NogoReceptor抗体;NogoReceptor Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Nogo Receptor expression in HepG2 cell lysate.    

  
  

NogoReceptor (NgR1), also known as the Nogo-66 receptor 1. is a key protein implicated in the regulation of axonal growth and neural plasticity within the central nervous system (CNS). Identified in the early 2000s, NgR1 binds to myelin-associated inhibitors (MAIs) such as Nogo-A, MAG, and OMgp, which are expressed in CNS myelin and act as potent suppressors of neurite outgrowth. These inhibitory signals are critical for maintaining neural circuit stability but hinder axon regeneration following injury, contributing to the limited regenerative capacity of the adult CNS.

NgR1 is a glycosylphosphatidylinositol (GPI)-anchored receptor, part of a larger receptor complex that includes co-receptors like p75NTR, TROY, or LINGO-1. which transduce inhibitory signals via the RhoA/ROCK pathway. This signaling cascade leads to cytoskeletal destabilization, growth cone collapse, and ultimately, failure of axonal repair. Antibodies targeting NgR1 (anti-NgR1 antibodies) aim to block its interaction with MAIs, thereby neutralizing inhibitory signaling and promoting axonal sprouting or regeneration.

Preclinical studies in spinal cord injury and stroke models have shown that NgR1 antibodies enhance functional recovery, making them promising therapeutic candidates for CNS trauma and neurodegenerative diseases. However, challenges remain, including optimizing specificity, delivery across the blood-brain barrier, and balancing regenerative effects with potential disruptions to neural plasticity. Current research focuses on refining antibody design and exploring combinatorial approaches with other pro-regenerative therapies.